Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Emblem Corp EMMBF

"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."

OTCPK:EMMBF - Post Discussion

Emblem Corp > Emblem Positioned to be Disruptive in Medical Cannabis
View:
Post by HeebieJeebies on Oct 11, 2017 9:22am

Emblem Positioned to be Disruptive in Medical Cannabis

https://www.baystreet.ca/stockstowatch/2299/Emblem-Positioned-to-be-Disruptive-in-the-Medical-Cannabis-Industry
Comment by ledrog on Oct 11, 2017 9:39am
For $4,000 they better write something good...
Comment by deminimis on Oct 11, 2017 9:41am
They expect to begin selling the pain release medication by fall 2018? Damn, that is much sooner than I expected. Glad to see they are actually trying to promote the stock again.
Comment by tarnoir on Oct 11, 2017 3:11pm
They need to get their grow room production going - expansion etc. In order to compete in this marketplace - they are a piss ant compared to the big 4.
Comment by cressco on Oct 11, 2017 3:59pm
I thought the same thing, I guess pain studies aren't as time consuming. I also like this quote from the last news release: "......We are also looking forward to further collaborations with Canntab to bring other groundbreaking cannabis-based advanced dosage forms to the market." Regards
Comment by deminimis on Oct 11, 2017 4:45pm
I don't think it has anything to do with the fact that it is pain medication. As the article states, traditional pharmaceutical drugs (including pain drugs) typically take 5-10 years to develop, complete clinical trials and gain approval to sell. I imagine most of that time frame is dedicated to evaluating potential side effects. I presume the fact that the side effects of cannabis are already ...more  
Comment by cressco on Oct 11, 2017 5:04pm
Thanks for clarifying. Awful assumption on my behalf as I only skimmed through and the answer was right in the article. It does make sense that the reason would be the known side effect profile of cannabis.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse